PRMA Consulting || Improving Pharmaceutical Market Access in Asia-Pacific
Agilent SLIMS
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!

A Novel Therapy Discovered for the Treatment of Relapsed or Refractory Multiple Myeloma

Janssen discovered novel therapy, Teclistamab for the treatment of relapsed or refractory multiple myeloma.

Teclistamab is an off-the-shelf, T-cell redirecting, bispecific antibody which targets both B-Cell Maturation Antigen (BCMA) and CD3 receptors. Moreover, it redirects the CD3-positive T-cells to BCMA-expressing myeloma cells and kills the growth of tumour cells.

Multiple myeloma an incurable blood cancer affecting the type of white blood cell called plasma cells usually found in bone marrow. These plasma cells when damaged are supposed to quickly spread and replace normal cells with tumors in the bone marrow. Studies have suggested that teclistamab kills myeloma cell lines and bone marrow-derived myeloma cells from heavily pre-treated patients.

In 2021, it is estimated that approximately 35,000 people are diagnosed and more than 12,000 are expected to die with this disease in the U.S.

Initially patients with multiple myeloma have no symptoms. Patients are diagnosed due to symptoms such as tiredness, bone fracture or pain, low red blood cell counts, high calcium levels, kidney problems or infections.

U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for teclistamab in the treatment of relapsed or refractory multiple myeloma.

Latest Issue
Get instant
access to our latest e-book
Saving Money, Saving Time In Pharma Operations Thermo Fisher Scientific || Revolutionize your mAb manufacturing Kerry || Webinar || Coatings Change Control Webinar || Recording-Webinar Rousselot || X-PureĀ® GelMA Meco - 90 years Medical Fair Thailand 2022